Breakthrough injection slashes Sky-High fats in rare genetic disease
NCT ID NCT05902598
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times
Summary
This study tested an injectable drug called Plozasiran in 37 Chinese adults with Familial Chylomicronemia Syndrome (FCS), a rare genetic disorder causing extremely high blood fats that can lead to severe pancreatitis. The main goal was to see if the drug safely lowers triglyceride levels after 10 months of treatment. Participants received either the drug or a placebo for up to 2 years, followed by an open-label extension where everyone gets the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL CHYLOMICRONEMIA SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.